Ranibizumab for retinal vein occlusion: Predictive factors and long-term outcomes in real-life data

Retina

Volumn 38, Issue 3, 2018, Pages 559-568

  Chatziralli, Irini ^a,b   Theodossiadis, George ^c   Chatzirallis, Alexandros ^b   Parikakis, Efstratios ^b   Mitropoulos, Panagiotis ^b   Theodossiadis, Panagiotis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Ophthalmiatrion Athinon ^*  (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Optical coherence tomography; Predictive factors; Ranibizumab; Retinal vein occlusion

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INTRARETINAL FLUID; LONG TERM CARE; MACULAR EDEMA; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RETINA EDEMA; RETROSPECTIVE STUDY; RISK FACTOR; VISION; AGE; COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RETINA MACULA LUTEA; RETINA VEIN OCCLUSION; SUBRETINAL FLUID; VISUAL ACUITY;

AGE FACTORS; AGED; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS; SUBRETINAL FLUID; VISUAL ACUITY;

EID: 85014126896     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001579     Document Type: Article

References (30)

1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133–141.
2. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2000;117:313–319.
3. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111–131.
4. Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 2013;33:901–910.
5. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726–732.
6. Yau JW, Lee P, Wong TY, et al. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008;38:904–910.
7. Deobhakta A, Chang LK. Inflammation in retinal vein occlusion. Int J Inflam 2013;2013:438412.
8. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 2013;120:795–802.
9. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644–1650.
10. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008; 22:42–48.
11. Noma H, Mimura T, Eguchi S. Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol 2013;131:160–165.
12. Jung SH, Kim KA, Sohn SW, Yang SJ. Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. Invest Ophthalmol Vis Sci 2014;55:2290–2296.
13. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041–2049.
14. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594–1602.
15. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119: 802–809.
16. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014;121: 209–219.
17. Minami Y, Nagaoka T, Ishibazawa A, Yoshida A. Short-term effect of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion. Retina 2016;36: 1726–1732.
18. Farinha C, Marques JP, Almeida E, et al. Treatment of retinal vein occlusion with ranibizumab in clinical practice: longer-term results and predictive factors of functional outcome. Ophthalmic Res 2015;55:10–18.
19. Rezar S, Eibenberger K, Bühl W, et al. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years. Acta Ophthalmol 2015;93:719–725.
20. Sakanishi Y, Ouchi A, Ito R, Ebihara N. Six months outcome in patients with macular edema due to retinal vein occlusion treated with ranibizumab [in Japanese]. Nippon Ganka Gakkai Zasshi 2016;120:28–34.
21. Larsen M, Waldstein SM, Boscia F, et al. Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 2016;12395:1101–1111.
22. Tadayoni R, Waldstein SM, Boscia F, et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 2016;123:1332–1344.
23. Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, et al. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci 2011;52:3334–3337.
24. Ota M, Tsujikawa A, Murakami T, et al. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 2007;91: 1644–1649.
25. Murakami T, Tsujikawa A, Ohta M, et al. Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol 2007;143:171–173.
26. Chatziralli IP, Sergentanis TN, Sivaprasad S. Hyperreflec-tive foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab. Retina 2016; 36:2319–2328.
27. Rotsos TG, Moschos MM. Cystoid macular edema. Clin Ophthalmol 2008;2:919–930.
28. Roberts P, Mittermueller TJ, Montuoro A, et al. A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD. Invest Ophthalmol Vis Sci 2014;55:6623–6630.
29. Coscas G, Coscas F, Zucchiatti I, et al. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex. Eur J Ophthalmol 2011;21:631–636.
30. Sophie R, Hafiz G, Scott AW, et al. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol 2013;156:693–705.